ALKEON CAPITAL MANAGEMENT LLC 13D and 13G filings for Keros Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 4:12 pm Sale |
2024-12-31 | 13G | Keros Therapeutics, Inc. KROS |
ALKEON CAPITAL MANAGEMENT LLC | 1,101,000 2.700% |
-397,907 (-26.55%) |
Filing |
| 2024-02-13 6:38 pm Purchase |
2023-12-31 | 13G | Keros Therapeutics, Inc. KROS |
ALKEON CAPITAL MANAGEMENT LLC | 1,498,907 5.000% |
106,505 (+7.65%) |
Filing |
| 2023-02-13 10:13 am Purchase |
2022-12-31 | 13G | Keros Therapeutics, Inc. KROS |
ALKEON CAPITAL MANAGEMENT LLC | 1,392,402 5.100% |
1,392,402 (New Position) |
Filing |